Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

被引：0
|
作者：
Hofmeister, Craig C.
Chari, Ajai
Cohen, Yael
Spencer, Andrew
Voorhees, Peter M.
Estell, Jane
Venner, Christopher P.
Sandhu, Irwindeep
Jenner, Matthew W.
Williams, Cathy
Cavo, Michele
Van de Donk, Niels W. C. J.
Beksac, Meral
Kuppens, Steven
Bandekar, Rajesh
Neff, Tobias
Heuck, Christoph
Qi, Ming
Goldschmidt, Hartmut
Landgren, Ola
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
510
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF DARATUMUMAB MONOTHERAPY FOR PATIENTS (PTS) WITH INTERMEDIATE OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): CENTAURUS
    Cavo, M.
    Hofmeister, C. C.
    Chari, A.
    Cohen, Y. C.
    Spencer, A.
    Voorhees, P.
    Estell, J.
    Venner, C.
    Sandhu, I
    Jenner, M.
    Williams, C.
    van de Donk, N.
    Beksac, M.
    Kuppens, S.
    Bandekar, R.
    Neff, T.
    Heuck, C.
    Qi, M.
    Goldschmidt, H.
    Landgren, Ola C.
    HAEMATOLOGICA, 2018, 103 : 40 - 41
  • [2] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    Landgren, C. Ola
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter
    Estell, Jane A.
    Sandhu, Irwindeep
    Jenner, Matthew W.
    Williams, Catherine
    Cavo, Michele
    van de Donk, Niels W. C. J.
    Beksac, Meral
    Moreau, Philippe
    Goldschmidt, Hartmut
    Kuppens, Steven
    Bandekar, Rajesh
    Clemens, Pamela L.
    Neff, Tobias
    Heuck, Christoph
    Qi, Ming
    Hofmeister, Craig C.
    LEUKEMIA, 2020, 34 (07) : 1840 - 1852
  • [3] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    C. Ola Landgren
    Ajai Chari
    Yael C. Cohen
    Andrew Spencer
    Peter Voorhees
    Jane A. Estell
    Irwindeep Sandhu
    Matthew W. Jenner
    Catherine Williams
    Michele Cavo
    Niels W. C. J. van de Donk
    Meral Beksac
    Philippe Moreau
    Hartmut Goldschmidt
    Steven Kuppens
    Rajesh Bandekar
    Pamela L. Clemens
    Tobias Neff
    Christoph Heuck
    Ming Qi
    Craig C. Hofmeister
    Leukemia, 2020, 34 : 1840 - 1852
  • [4] A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF ELOTUZUMAB MONOTHERAPY IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA
    Richardson, P.
    Wong, E.
    Stockerl-Goldstein, K.
    Rosenbaum, C.
    Dhodapkar, M.
    Jou, Y. M.
    Lynch, M.
    Robbins, M.
    Bleickardt, E.
    Jagannath, S.
    HAEMATOLOGICA, 2016, 101 : 328 - 329
  • [5] Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)
    Landgren, Ola
    Cavo, Michele
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter M.
    Estell, Jane
    Sandhu, Irwindeep
    Jenner, Matthew
    Williams, Catherine
    van de Donk, Niels W. C. J.
    Beksac, Meral
    Goldschmidt, Hartmut
    Moreau, Philippe
    Kuppens, Steven
    Bandekar, Rajesh
    Neff, Tobias
    Cortoos, Annelore
    Clemens, Pamela L.
    Qi, Ming
    Adams, Homer, III
    Hofmeister, Craig C.
    BLOOD, 2018, 132
  • [6] Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with IntermediateRisk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study
    Landgren, Ola
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter M.
    Sandhu, Irwindeep
    Jenner, Matthew W.
    Smith, Dean
    Cavo, Michele
    van de Donk, Niels Wcj
    Beksac, Meral
    Moreau, Philippe
    Goldschmidt, Hartmut
    Sha, Linlin
    Li, Liang
    Rousseau, Els
    Dennis, Robyn
    Carson, Robin
    Hofmeister, Craig C.
    BLOOD, 2023, 142
  • [7] Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
    Chari, Ajai
    Munder, Markus
    Weisel, Katja
    Jenner, Matthew
    Bygrave, Ceri
    Petrucci, Maria Teresa
    Boccadoro, Mario
    Cavo, Michele
    van de Donk, Niels W. C. J.
    Turgut, Mehmet
    Demirkan, Fatih
    Karadogan, Ihsan
    Libby, Edward
    Kleiman, Robert
    Kuppens, Steven
    Bandekar, Rajesh
    Neff, Tobias
    Heuck, Christoph
    Qi, Ming
    Clemens, Pamela L.
    Goldschmidt, Hartmut
    ADVANCES IN THERAPY, 2021, 38 (02) : 1328 - 1341
  • [8] Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
    Ajai Chari
    Markus Munder
    Katja Weisel
    Matthew Jenner
    Ceri Bygrave
    Maria Teresa Petrucci
    Mario Boccadoro
    Michele Cavo
    Niels W. C. J. van de Donk
    Mehmet Turgut
    Fatih Demirkan
    Ihsan Karadogan
    Edward Libby
    Robert Kleiman
    Steven Kuppens
    Rajesh Bandekar
    Tobias Neff
    Christoph Heuck
    Ming Qi
    Pamela L. Clemens
    Hartmut Goldschmidt
    Advances in Therapy, 2021, 38 : 1328 - 1341
  • [9] Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.
    Dimopoulos, Meletios A.
    Voorhees, Peter M.
    Goldschmidt, Hartmut
    Baker, Ross I.
    Shi, Yingqi
    Rousseau, Els
    Dennis, Robyn Monet
    Carson, Robin L.
    Rajkumar, S. Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.
    Rajkumar, S. Vincent
    Voorhees, Peter Michael
    Goldschmidt, Hartmut
    Baker, Ross I.
    Bandekar, Rajesh
    Kuppens, Steven
    Neff, Tobias
    Qi, Ming
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345